Citations

Showing 10 of 108081 citations.

Association of Long-term Opioid Therapy With Functional Status, Adverse Outcomes, and Mortality Among Patients With Polyneuropathy
Hoffman, E. Matthew , Watson, James C. , Sauver, Jennifer L. St. , Staff, Nathan P. , Klein, Christopher J. , St Sauver, Jennifer, Staff, Nathan P , Klein, Christopher J , St Sauver, Jennifer L

Mayo Clinic

JAMA Neurology | May 22, 2017 | Volume: 74 | Issue: 7 | Pages: 773

10.1001/jamaneurol.2017.0486 | PMID 28531306 Get It

Intracranial Gadolinium Deposition Following Gadodiamide-Enhanced Magnetic Resonance Imaging in Pediatric Patients
McDonald, Robert J. , Jentoft, Mark E. , Paolini, Michael A., Murray, David , Kallmes, David F. , Eckel, Laurence J. , Murray, David L., McDonald, Jennifer S.

Mayo Clinic

JAMA Pediatrics | May 22, 2017 | Volume: 171 | Issue: 7 | Pages: 705

10.1001/jamapediatrics.2017.0264 | PMID 28531274 Get It

Meeting Report of the Fifth International Cancer Epigenetics Conference in Beijing, China, October 2016
Gao, Dan , Herman, James G. , Cui, Hengmi , Jen, Jin , Fuks, François , Brock, Malcolm V., Ushijima, Toshikazu , Guo, Mingzhou , Croce, Carlo Maria , Akiyama, Yoshimitsu

Mayo Clinic

Epigenomics | May 22, 2017 | Volume: 9 | Issue: 7 | Pages: 937-941

10.2217/epi-2017-0030 | PMID 28530839 Get It

Identifying Therapeutic Targets for Alzheimer’s Disease With Big Data
Ertekin‐Taner, Nilüfer

Mayo Clinic

Neurodegenerative Disease Management | May 22, 2017 | Volume: 7 | Issue: 2 | Pages: 101-105

10.2217/nmt-2017-0008 | PMID 28540771 Get It

Repeatability of MR Elastography of Liver: A Meta-Analysis
Serai, Suraj D. , Obuchowski, Nancy A. , Venkatesh, Sudhakar K. , Miller, Frank H. , Ashton, Edward, Cole, Patricia E., Sirlin, Claude B. , Ehman, Richard L. , Venkatesh, Sudhakar K , Serai, Suraj D , Miller, Frank H

Mayo Clinic

Radiology | May 22, 2017 | Volume: 285 | Issue: 1 | Pages: 92-100

10.1148/radiol.2017161398 | PMID 28530847 Get It

Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study
Golan, Talia , Raitses‐Gurevich, Maria , Kelley, Robin Kate , Bocobo, Andrea Grace, Borgida, Ayelet , Shroff, Rachna T. , Holter, Spring, Gallinger, Steven , Ahn, Daniel H. , Aderka, Dan, Jain, Apurva , Bekaii‐Saab, Tanios , Friedman, Eitan , Javle, Milind , Bekaii-Saab, Tanois, Bekaii-Saab, Tanios S

Mayo Clinic

The Oncologist | May 22, 2017 | Volume: 22 | Issue: 7 | Pages: 804-810

10.1634/theoncologist.2016-0415 | PMID 28487467 Get It

Abstract Background Biliary tract malignancies, in particular cholangiocarcinomas (CCA), are rare tumors that carry a poor prognosis. BRCA2 mutation carriers have an increased risk of developing CCA with a reported relative risk of ∼5 according to the Breast Cancer Linkage Consortium. In addition to this risk, there are potential therapeutic implications in those harboring somatic and/or germline (GL) BRCA mutations. Therefore, it is important to define the clinical characteristics of GL/somatic BRCA1/2 variants in CCA patients. Materials and Methods We performed a multicenter retrospective analysis of CCA patients diagnosed between January 2000 and December 2013 with GL or somatic variants in BRCA1/2 genes detected by GL mutations testing and/or by tumor next generation sequencing. Cases were identified from clinical databases at participating institutions. Data including demographics, clinical history, surgical procedures, and systemic chemotherapy or radiation were extracted from patients' records. Results Overall, 18 cases were identified: 5 carriers of GL BRCA1/2 mutations (4 BRCA2; 1 BRCA1) and 13 harboring somatic variations (7 BRCA1; 6 BRCA2). Mean age at diagnosis was 60, SD ± 10 years (range 36–75 years), with male and female prevalence rates of 61.2% and 38.8%, respectively. Stage at diagnosis was I (n = 4), II (n = 3), III (n = 3), and IV (n = 8). Six patients had extrahepatic CCA and the rest intrahepatic CCA. Thirteen patients received platinum-based therapy and four were treated with poly ADP ribose polymerase inhibitors, of whom one experienced sustained disease response with a progression-free survival of 42.6 months. Median overall survival from diagnosis for patients with stage I/II in this study was 40.3 months (95% confidence interval [CI], 6.73–108.15) and with stages III/IV was 25 months (95% CI, 15.23–40.57). Conclusion BRCA-associated CCA is uncommon. This multicenter retrospective study provides a thorough clinical analysis of a BRCA-associated CCA cohort, which can serve as a benchmark for future development and design of expanded analyses and clinical trials.
A Combination of a Polycaprolactone Fumarate Scaffold with Polyethylene Terephthalate Sutures for Intra-Articular Ligament Regeneration
Parry, Joshua A. , Wagner, Eric R. , Kok, Peter L., Dadsetan, Mahrokh, Yaszemski, Michael J. , Wijnen, André J. van , van Wijnen, Andre J, Kakar, Sanjeev , van Wijnen, Andre J , Wagner, Eric R

Mayo Clinic

Tissue Engineering Part A | May 20, 2017 | Volume: 24 | Issue: 3-4 | Pages: 245-253

10.1089/ten.tea.2016.0531 | PMID 28530131 Get It

Effectiveness of a Decision Aid in Potentially Vulnerable Patients: A Secondary Analysis of the Chest Pain Choice Multicenter Randomized Trial
Schaffer, Jason T. , Kline, Jeffrey A. , Diercks, Deborah B. , Jones, Russell, Demers, Michel, Shah, Nilay D. , Inselman, Jonathan , Torres, Carlos A, Rising, Kristin L. , Hollander, Judd E. , Torres, Carlos A., Owen, Kelly P. , Meisel, Zachary F. , LeBlanc, Annie , Herrin, Jeph , Montori, Víctor M. , Hess, Erik P.

Mayo Clinic

Medical Decision Making | May 19, 2017 | Volume: 38 | Issue: 1 | Pages: 69-78

10.1177/0272989x17706363 | PMID 28525723 Get It

Background. We test the hypotheses that use of the Chest Pain Choice (CPC) decision aid (DA) would be similarly effective in potentially vulnerable subgroups but increase knowledge more in patients with higher education and trust in physicians more in patients from racial minority groups. Methods. This was a secondary analysis of a multicenter randomized trial in adults with chest pain potentially due to acute coronary syndrome. The trial compared an intervention group engaged in shared decision making (SDM) using CPC to a control group receiving usual care (UC). We assessed for subgroup effects based on age, sex, race, income, insurance, education, literacy, and numeracy. We dichotomized each characteristic and tested for interactions using regression models with indicators for arm assignment and study site. Results. Of 898 patients (451 DA, 447 UC), over 50% were female, over one-third were black, nearly one-third had a high school education or less, and over 60% had “low” health literacy. The DA did not increase knowledge more in patients with higher education ( P for interaction = 0.06) but did increase knowledge more in the “typical” than in the “low” numeracy subgroup (10.6% v. 4.7%, absolute difference [AD] = 5.9%, P for interaction = 0.025). The DA did not significantly increase patient trust in physicians in racial minorities ( P for interaction = 0.06) but did increase trust more in patients with “low” literacy compared with those with “typical” literacy (3.7% v. –1.4%, AD = 5.1, P for interaction = 0.011). Conclusions. CPC benefited all sociodemographic groups to a similar extent, with greater knowledge transfer in patients with higher numeracy and greater physician trust in patients with “low” health literacy. Tailoring SDM interventions to patient characteristics may be necessary for optimal effectiveness.
Long-term risk of recurrence and regrowth after gross-total and subtotal resection of sporadic vestibular schwannoma
Jacob, Jeffrey T. , Carlson, Matthew L. , Tanaka, Shota , Tanaka, Minoru , Saito, Nobuhito , Lohse, Christine M. , Driscoll, Colin L. W., Link, Michael J. , Nakatomi, Hirofumi

Mayo Clinic

Journal of Neurosurgery | May 19, 2017 | Volume: 133 | Issue: 4 | Pages: 1052-1058

10.3171/2016.11.jns16498 | PMID 28524795 Get It

OBJECTIVEThe management of vestibular schwannoma (VS) remains controversial. One commonly cited advantage of microsurgery over other treatment modalities is that tumor removal provides the greatest chance of long-term cure. However, there are very few publications with long-term follow-up to support this assertion. The purpose of the current study is to report the very long-term risk of recurrence among a large historical cohort of patients who underwent microsurgical resection.METHODSThe authors retrospectively reviewed the medical records of patients who had undergone primary microsurgical resection of unilateral VS via a retrosigmoid approach performed by a single neurosurgeon-neurotologist team between January 1980 and December 1999. Complete tumor removal was designated gross-total resection (GTR), and anything less than complete removal was designated subtotal resection (STR). The primary end point was radiological recurrence-free survival. Time-to-event analyses were performed to identify factors associated with recurrence.RESULTSFour hundred fourteen patients met the study inclusion criteria and were analyzed. Overall, 67 patients experienced recurrence at a median of 6.9 years following resection (IQR 3.9–12.1, range 1.2–22.5 years). Estimated recurrence-free survival rates at 5, 10, 15, and 20 years following resection were 93% (95% CI 91–96, 248 patients still at risk), 78% (72–85, 88), 68% (60–77, 47), and 51% (41–64, 22), respectively. The strongest predictor of recurrence was extent of resection, with patients who underwent STR having a nearly 11-fold greater risk of recurrence than the patients treated with GTR (HR 10.55, p < 0.001). Among the 18 patients treated with STR, 15 experienced recurrence at a median of 2.7 years following resection (IQR 1.9–8.9, range 1.2–18.7). Estimated recurrence-free survival rates at 5, 10, 15, and 20 years following GTR were 96% (95% CI 93–98, 241 patients still at risk), 82% (77–89, 86), 73% (65–81, 46), and 56% (45–70, 22), respectively. Estimated recurrence-free survival rates at 5, 10, and 15 years following STR were 47% (95% CI 28–78, 7 patients still at risk), 17% (5–55, 2), and 8% (1–52, 1), respectively.CONCLUSIONSLong-term surveillance is required following microsurgical resection of VS even after GTR. Subtotal resection alone should not be considered a definitive long-term cure. These data emphasize the importance of long-term follow-up when reporting tumor control outcomes for VS.